Acetaminophen Given Per Os and Intravenous in Sinus Surgery

Sponsor
Massachusetts Eye and Ear Infirmary (Other)
Overall Status
Unknown status
CT.gov ID
NCT03295214
Collaborator
(none)
124
1
2
23.1
5.4

Study Details

Study Description

Brief Summary

The primary objective of this study is to investigate the Visual Analog Score (VAS) for pain within the post-operative setting and determine if there is a statistically significant difference between the VAS for PO or IV acetaminophen. It is expected that in doing so the investigators can produce the maximal amount of pain relief after surgery while making conscientious monetary decisions.

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

Functional Endoscopic Sinus Surgery (FESS) is one of the most common Ear Nose and Throat Surgeries done in the United States annually. This procedure can vary from intense to moderate pain and as such it is difficult to properly gauge and treat postoperative pain in these patients. Commonly used in these cases, opioid drugs are given to provide adequate analgesia, however higher opioid usage is observed to cause increased Post-Anesthesia Care Unit (PACU) stays, respiratory complications and Postoperative Nausea and Vomiting (PONV). Acetaminophen is commonly used as an adjunct in these circumstances because of its opioid sparing properties.

Acetaminophen is a synthetic nonopioid p-aminophenol derivative available over the counter. Its properties include analgesic and antipyretic qualities and it is listed on the world health organization's list of essential medicines. The potential risks include liver damage, skin reactions and drug interactions when used with blood thinners at high doses. Acetaminophen has been extensively researched, in vitro and in vivo studies have found the drug to be safe when used at proper doses. Recently intravenous use of acetaminophen has gained popularity due to ease of use and ability to be given intraoperatively. This form of acetaminophen, although convenient, is around sixty two times the cost of oral acetaminophen. Due to this increased cost it is imperative that the investigators compare the two routes of administration in order to determine if the additional cost is justified.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
124 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
A Prospective Clinical Trial Evaluating the Post-Operative Analgesic Effects of Acetaminophen Given Per Os and Intravenous
Actual Study Start Date :
Mar 28, 2018
Anticipated Primary Completion Date :
Mar 1, 2020
Anticipated Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Acetaminophen 975mg Per Os

975mg of Acetaminophen given by mouth

Drug: Acetaminophen
Acetaminophen given for pain relief

Active Comparator: Acetaminophen 1000mg Intravenous

1000mg of Acetaminophen given intravenously

Drug: Acetaminophen
Acetaminophen given for pain relief

Outcome Measures

Primary Outcome Measures

  1. VAS for pain [0-1 hour]

    First VAS pain score applied

Secondary Outcome Measures

  1. Opioid Use [24 hours]

    Postoperative opioid consumption for pain control

  2. Time in PACU [3-5 hours]

    Time required to be admitted and discharged home

  3. VAS for pain [1-2 hours]

    Second VAS pain score applied

  4. VAS for pain [2-3 hours]

    Third VAS pain score applied

  5. VAS for pain [24 hours]

    Last VAS pain score applied

  6. PONV [24 hours]

    Incidence of PONV

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Willingness to participate

  • Undergoing FESS surgery at Massachusetts Eye and Ear (MEE)

  • Over the age of 18 during time of surgery

  • Weighing over 50kg

Exclusion Criteria:
  • Severe hepatic impairment or active liver disease

  • Known hypersensitivity to acetaminophen or to any excipients in the intravenous formulation

  • chronic opioid use

  • chronic pain

  • alcohol or drug abuse

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts Eye and Ear Boston Massachusetts United States 02114

Sponsors and Collaborators

  • Massachusetts Eye and Ear Infirmary

Investigators

  • Principal Investigator: Iuliu Fat, MD, MEEI

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Luliu Fat, Principal Investigator, Massachusetts Eye and Ear Infirmary
ClinicalTrials.gov Identifier:
NCT03295214
Other Study ID Numbers:
  • 1098410
First Posted:
Sep 27, 2017
Last Update Posted:
Apr 10, 2019
Last Verified:
Apr 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Luliu Fat, Principal Investigator, Massachusetts Eye and Ear Infirmary
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 10, 2019